Join Free
Menu


Imugene Limited
Level 12/4-6 Bligh St
Sydney, NSW 2000
Australia
Imugene is a clinical-stage immuno-oncology company developing a range of new treatments designed to activate the immune system of cancer patients to identify and eradicate tumors. Our unique platform technologies aim to harness the body’s immune system against tumors, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibodies and other immunotherapies.

We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies, many of which have been approved for sale and marketing in global markets. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR-T drug, Azer-cel (azercabtagene zapreleucel), which targets CD19 to treat blood cancers. Additionally, our pipeline features multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating various cancers.